A multi-target approach for pain treatment: Dual inhibition of fatty acid amide hydrolase and TRPV1 in a rat model of osteoarthritis

Pain

Volumn 156, Issue 5, 2015, Pages 890-903

  Malek, Natalia ^a   Mrugala, Monika ^a   Makuch, Wioletta ^a   Kolosowska, Natalia ^a   Przewlocka, Barbara ^a   Binkowski, Marcin ^b   Czaja, Martyna ^b   Morera, Enrico ^c   Di Marzo, Vincenzo ^d   Starowicz, Katarzyna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b UNIVERSITY OF SILESIA   (Poland)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d CNR   (Italy)

Author keywords

Anandamide; CB 1; Endocannabinoid; FAAH; Osteoarthritis; Pain; TRPV1

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 4 CHLORO N (3 METHOXYPHENYL)CINNAMAMIDE; ACTIVATING TRANSCRIPTION FACTOR 3; ANALGESIC AGENT; CANNABINOID 1 RECEPTOR; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; INTERLEUKIN 6; MESSENGER RNA; OLVANIL; OMDM 198; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 1 ANTAGONIST; AMIDASE; AMIDE; ANANDAMIDE; ANILIDE; ARACHIDONIC ACID DERIVATIVE; ATF3 PROTEIN, RAT; BENZAMIDE DERIVATIVE; CAPSAICIN; CARBAMIC ACID DERIVATIVE; CINNAMIC ACID DERIVATIVE; CYCLOHEXYL CARBAMIC ACID 3'-CARBAMOYLBIPHENYL-3-YL ESTER; ENDOCANNABINOID; FATTY-ACID AMIDE HYDROLASE; N-(3-METHOXYPHENYL)-4-CHLOROCINNAMANILIDE; OMDM-198; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; TRPV1 PROTEIN, RAT; VANILLOID RECEPTOR;

ANALGESIA; ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; MALE; MICRO-COMPUTED TOMOGRAPHY; NERVE INJURY; NONHUMAN; OSTEOARTHRITIS; PAIN MEASUREMENT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPINAL GANGLION; UPREGULATION; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HYPERALGESIA; IMMUNOLOGY; INFLAMMATION; LUMBAR VERTEBRA; METABOLISM; PAIN; PATHOPHYSIOLOGY; PROCEDURES; WISTAR RAT;

ACTIVATING TRANSCRIPTION FACTOR 3; AMIDOHYDROLASES; ANILIDES; ANIMALS; ARACHIDONIC ACIDS; BENZAMIDES; CAPSAICIN; CARBAMATES; CINNAMATES; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; GANGLIA, SPINAL; GENE EXPRESSION; HYPERALGESIA; INFLAMMATION; INTERLEUKIN-6; LUMBAR VERTEBRAE; MALE; OSTEOARTHRITIS; PAIN; PAIN MANAGEMENT; PAIN MEASUREMENT; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; TRPV CATION CHANNELS;

EID: 84945298064     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1097/j.pain.0000000000000132     Document Type: Article

References (75)

1. Ahn K, Smith SE, Liimatta MB, Beidler D, Sadagopan N, Dudley DT, Young T, Wren P, Zhang Y, Swaney S, Van Becelaere K, Blankman JL, Nomura DK, Bhattachar SN, Stiff C, Nomanbhoy TK, Weerapana E, Johnson DS, Cravatt BF. Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain. J Pharmacol Exp Ther 2011;338:114-24.
2. Baker CL, McDougall JJ. The cannabinomimetic arachidonyl-2- chloroethylamide (ACEA) acts on capsaicin-sensitive TRPV1 receptors but not cannabinoid receptors in rat joints. Br J Pharmacol 2004;142:1361-7.
3. Barton NJ, Strickland IT, Bond SM, Brash HM, Bate ST, Wilson AW, Chessell IP, Reeve AJ, McQueen DS. Pressure application measurement (PAM): a novel behavioural technique for measuring hypersensitivity in a rat model of joint pain. J Neurosci Methods 2007;163:67-75.
4. Binkowski M, Davis GR, Wrobel Z, Goodship AE. 6th World Congress of Biomechanics (WCB 2010). August 1-6, 2010 Singapore. Lim CT, Goh JCH, editors. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. p. 856-859.
5. Binkowski M, Kokot G, Bolechala F, John A. Image-based finite element modeling of the three-point bending test of cortical bone. In: Stock SR, editor. Proc. SPIE 8506, developments in x-ray tomography VIII, 85060D, 2012. p. 85060D.
6. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001;134:845-52.
7. Bisogno T, Melck D, De Petrocellis L, MYu Bobrov, Gretskaya NM, Bezuglov VV, Sitachitta N, Gerwick WH, Di Marzo V. Arachidonoyl serotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun 1998;248:515-22. Available at: http:// www.ncbi.nlm.nih.gov/pubmed/9703957.
8. Bjordal JM, Klovning A, Ljunggren AE, Slørdal L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta-analysis of randomised placebo-controlled trials. Eur J Pain 2007;11:125-38.
9. Bove SE, Calcaterra SL, Brooker RM, Huber CM, Guzman RE, Juneau PL, Schrier DJ, Kilgore KS.Weight bearing as ameasure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. Osteoarthritis Cartilage 2003;11: 821-30. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14609535.
10. Burr DB, Gallant MA. Bone remodelling in osteoarthritis. Nat Rev Rheumatol 2012;8:665-73.
11. Chang L, Luo L, Palmer JA, Sutton S, Wilson SJ, Barbier AJ, Breitenbucher JG, Chaplan SR, Webb M. Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol 2006;148:102-13.
12. Chu KL, Chandran P, Joshi SK, Jarvis MF, Kym PR, McGaraughty S. TRPV1-related modulation of spinal neuronal activity and behavior in a rat model of osteoarthritic pain. Brain Res 2011;1369:158-66.
13. Costa B, Colleoni M, Conti S, Trovato AE, Bianchi M, Sotgiu ML, Giagnoni G. Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a ratmodel of neuropathic pain. Br J Pharmacol 2004;141:4-8.
14. Costa SKP, Teles AM, Kumagai Y, Brain SD, Teixeira SA, Varriano AA, Barreto MAG, de Lima WT, Antunes E, MuscaráMN. Involvement of sensory nerves and TRPV1 receptors in the rat airway inflammatory response to two environment pollutants: diesel exhaust particles (DEP) and 1,2-naphthoquinone (1,2-NQ). Arch Toxicol 2010;84:109-17.
15. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 2001;98:9371-6.
16. Cui M, Honore P, Zhong C, Gauvin D, Mikusa J, Hernandez G, Chandran P, Gomtsyan A, Brown B, Bayburt EK, Marsh K, Bianchi B, McDonald H, Niforatos W, Neelands TR, Moreland RB, Decker MW, Lee C-H, Sullivan JP, Faltynek CR. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists. J Neurosci 2006;26:9385-93.
17. Cyganik Ł, Binkowski M, Kokot G, Rusin T, Popik P, Bolechała F, Nowak R, Wróbel Z, J A. Prediction of Young' s modulus of trabeculae in microscale using macro-scale' s relationships between bone density and mechanical properties. J Mech Behav Biomed Mater 2014;36C:120-34.
18. DiMarzo V. Inhibitors of endocannabinoid breakdown for pain: not so FA(AH)cile, after all. PAIN 2012;153:1785-6.
19. Donaldson LF.Unilateral arthritis: contralateral effects. TrendsNeurosci 1999; 22:495-6. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10530993.
20. Fernihough J, Gentry C, Malcangio M, Fox A, Rediske J, Pellas T, Kidd B, Bevan S, Winter J. Pain related behaviour in two models of osteoarthritis in the rat knee. PAIN 2004;112:83-93.
21. Filipek J, Binkowski M, Maciejewska K, Drzazga Z, Wróbel Z. Investigation of microstructure of bone tissue inmandibles of newborn rats aftermaternal treatment with antiretroviral drugs. Biocybern Biomed Eng 2014.
22. Fowler CJ, Tiger G, López-Rodríguez ML, Viso A, Ortega-Gutiérrez S, Ramos JA. Inhibition of fatty acid amidohydrolase, the enzyme responsible for the metabolism of the endocannabinoid anandamide, by analogues of arachidonoyl-serotonin. J Enzyme Inhib Med Chem 2003;18:225-31. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14506913.
23. Gatta L, Piscitelli F, Giordano C, Boccella S, Lichtman A, Maione S, Di Marzo V. Discovery of prostamide F2a and its role in inflammatory pain and dorsal horn nociceptive neuron hyperexcitability. PLoS One 2012;7: e31111.
24. Gavva NR, Bannon AW, Hovland DN, Lehto SG, Klionsky L, Surapaneni S, Immke DC, Henley C, Arik L, Bak A, Davis J, Ernst N, Hever G, Kuang R, Shi L, Tamir R, Wang J, Wang W, Zajic G, Zhu D, Norman MH, Louis JC, Magal E, Treanor JJS. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade. J Pharmacol Exp Ther 2007;323:128-37.
25. Goldring MB, Marcu KB. Cartilage homeostasis in health and rheumatic diseases. Arthritis Res Ther 2009;11:224.
26. Guingamp C, Gegout-Pottie P, Philippe L, Terlain B, Netter P, Gillet P. Mono-iodoacetate-induced experimental osteoarthritis: a doseresponse study of loss of mobility, morphology, and biochemistry. Arthritis Rheum 1997;40:1670-9.
27. Guzman RE, Evans MG, Bove S, Morenko B, Kilgore K. Monoiodoacetate- induced histologic changes in subchondral bone and articular cartilage of rat femorotibial joints: an animal model of osteoarthritis. Toxicol Pathol;31:619-24. Available at: http://www.ncbi. nlm.nih.gov/pubmed/14585729.
28. Halvorson KG, Sevcik MA, Ghilardi JR, Rosol TJ, Mantyh PW. Similarities and differences in tumor growth, skeletal remodeling and pain in an osteolytic and osteoblastic model of bone cancer. Clin J Pain 2006;22: 587-600.
29. Hannan MT, Felson DT, Pincus T. Analysis of the discordance between radiographic changes and knee pain in osteoarthritis of the knee. J Rheumatol 2000;27:1513-7. Available at: http://www.ncbi.nlm.nih. gov/pubmed/10852280.
30. Hohmann AG. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids 2002;121:173-90. Available at: http:// www.ncbi.nlm.nih.gov/pubmed/12505699.
31. Honore P, Chandran P, Hernandez G, Gauvin DM, Mikusa JP, Zhong C, Joshi SK, Ghilardi JR, Sevcik MA, Fryer RM, Segreti JA, Banfor PN, Marsh K, Neelands T, Bayburt E, Daanen JF, Gomtsyan A, Lee CH, Kort ME, Reilly RM, Surowy CS, Kym PR, Mantyh PW, Sullivan JP, Jarvis MF, Faltynek CR. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia. PAIN 2009;142:27-35.
32. Honore P, Wismer CT, Mikusa J, Zhu CZ, Zhong C, Gauvin DM, Gomtsyan A, El Kouhen R, Lee C, Marsh K, Sullivan JP, Faltynek CR, Jarvis MF. A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)- urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. J Pharmacol Exp Ther 2005;314:410-21.
33. Huggins JP, Smart TS, Langman S, Taylor L, Young T. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. PAIN 2012;153:1837-46.
34. Hunter DJ, Zhang YQ, Niu JB, Tu X, Amin S, Clancy M, Guermazi A, Grigorian M, Gale D, Felson DT. The association of meniscal pathologic changes with cartilage loss in symptomatic knee osteoarthritis. Arthritis Rheum 2006;54:795-801.
35. Im HJ, Kim JS, Li X, Kotwal N, Sumner DR, vanWijnen AJ, Davis FJ, Yan D, Levine B, Henry JL, DesevréJ, Kroin JS. Alteration of sensory neurons and spinal response to an experimental osteoarthritis pain model. Arthritis Rheum 2010;62:2995-3005.
36. Janusz MJ, Hookfin EB, Heitmeyer SA, Woessner JF, Freemont AJ, Hoyland JA, Brown KK, Hsieh LC, Almstead NG, De B, Natchus MG, Pikul S, Taiwo YO. Moderation of iodoacetate-induced experimental osteoarthritis in rats by matrix metalloproteinase inhibitors. Osteoarthritis Cartilage 2001;9:751-60.
37. Jayamanne A, Greenwood R, Mitchell VA, Aslan S, Piomelli D, Vaughan CW. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 2006;147:281-8.
38. Kinsey SG, Long JZ, O'Neal ST, Abdullah RA, Poklis JL, Boger DL, Cravatt BF, Lichtman AH. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J Pharmacol Exp Ther 2009;330:902-10.
39. Kinsey SG, Naidu PS, Cravatt BF, Dudley DT, Lichtman AH. Fatty acid amide hydrolase blockade attenuates the development of collageninduced arthritis and related thermal hyperalgesia in mice. Pharmacol Biochem Behav 2011;99:718-25.
40. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005;5:400-11.
41. La Porta C, Bura SA, Negrete R, Maldonado R. Involvement of the endocannabinoid system in osteoarthritis pain. Eur J Neurosci 2014;39: 485-500.
42. Leuchtweis J, Imhof A-K, Montechiaro F, Schaible H-G, Boettger MK. Validation of the digital pressure application measurement (PAM) device for detection of primary mechanical hyperalgesia in rat and mouse antigen-induced knee joint arthritis. Methods Find Exp Clin Pharmacol 2010;32:575-83.
43. Limaye A. Drishti: a volume exploration and presentation tool. In: Stock SR, editor. Proc. SPIE 8506, developments in x-ray tomography VIII. 2012. p. 85060X.
44. Lo GH, Hunter DJ, Zhang Y, McLennan CE, Lavalley MP, Kiel DP, McLean RR, Genant HK, Guermazi A, Felson DT. Bone marrow lesions in the knee are associated with increased local bone density. Arthritis Rheum 2005;52:2814-21.
45. Maione S, Costa B, Piscitelli F, Morera E, De Chiaro M, Comelli F, Boccella S, Guida F, Verde R, Ortar G, Di Marzo V. Piperazinyl carbamate fatty acid amide hydrolase inhibitors and transient receptor potential channel modulators as "dual-target" analgesics. Pharmacol Res 2013; 76:98-105.
46. Maione S, De Petrocellis L, deNovellis V, Moriello AS, Petrosino S, Palazzo E, Rossi FS, Woodward DF, Di Marzo V. Analgesic actions of N-arachidonoylserotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol 2007;150:766-81.
47. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, Feldmann M. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 2000;97:9561-6.
48. Mbvundula EC, Rainsford KD, Bunning RAD. Cannabinoids in pain and inflammation. Inflammopharmacology 2004;12:99-114. doi:10.1163/ 1568560041352275.
49. Melemedjian OK, Tillu D V, Moy JK, Asiedu MN, Mandell EK, Ghosh S, Dussor G, Price TJ. Local translation and retrograde axonal transport of CREB regulates IL-6-induced nociceptive plasticity. Mol Pain 2014;10: 45. doi:10.1186/1744-8069-10-45.
50. Miller RE, Miller RJ, Malfait AM. Osteoarthritis joint pain: the cytokine connection. Cytokine 2014.
51. Morera E, De Petrocellis L, Morera L, Moriello AS, Ligresti A, Nalli M, Woodward DF, Di Marzo V, Ortar G. Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands. Bioorg Med Chem Lett 2009;19:6806-9.
52. Mukhopadhyay P, Horváth B, Rajesh M, Matsumoto S, Saito K, Bátkai S, Patel V, Tanchian G, Gao RY, Cravatt BF, HaskóG, Pacher P. Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury. Free Radic Biol Med 2011;50:179-95.
53. Naidu PS, Kinsey SG, Guo TL, Cravatt BF, Lichtman AH. Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase. J Pharmacol Exp Ther 2010;334:182-90.
54. Neogi T, Felson D, Niu J, Lynch J, Nevitt M, Guermazi A, Roemer F, Lewis CE, Wallace B, Zhang Y. Cartilage loss occurs in the same subregions as subchondral bone attrition: awithin-knee subregion-matched approach from the Multicenter Osteoarthritis Study. Arthritis Rheum 2009;61:1539-44.
55. Ortar G, Cascio MG, De Petrocellis L, Morera E, Rossi F, Schiano-Moriello A, Nalli M, de Novellis V, Woodward DF, Maione S, Di Marzo V. New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain. J Med Chem 2007;50:6554-69.
56. Patricelli MP, Lashuel HA, Giang DK, Kelly JW, Cravatt BF. Comparative characterization of a wild type and transmembrane domain-deleted fatty acid amide hydrolase: identification of the transmembrane domain as a site for oligomerization. Biochemistry 1998;37:15177-87.
57. Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol 2001;63: 569-611. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11164622.
58. Piscitelli F, Di Marzo V. "Redundancy" of endocannabinoid inactivation: new challenges and opportunities for pain control. ACS Chem Neurosci 2012;3:356-63.
59. Pomonis JD, Boulet JM, Gottshall SL, Phillips S, Sellers R, Bunton T, Walker K. Development and pharmacological characterization of a rat model of osteoarthritis pain. PAIN 2005;114:339-46.
60. Price TJ. Targeting eIF4E phosphorylation for the prevention and treatment of chronic pain. 15th World Congress on Pain, Topical Workshop no.27. Buenos Aires, Argentina, 2014.
61. Puttfarcken PS, Han P, Joshi SK, Neelands TR, Gauvin DM, Baker SJ, Lewis LGR, Bianchi BR, Mikusa JP, Koenig JR, Perner RJ, Kort ME, Honore P, Faltynek CR, Kym PR, Reilly RM. A-995662 [(R)-8-(4-methyl-5-(4- (trifluoromethyl)phenyl)oxazol-2-ylamino)-1,2,3,4-tetrahydronaphthalen-2- ol], a novel, selective TRPV1 receptor antagonist, reduces spinal release of glutamate and CGRP in a rat knee joint pain model. PAIN 2010;150: 319-26.
62. Richardson D, Pearson RG, Kurian N, Latif ML, Garle MJ, Barrett DA, Kendall DA, Scammell BE, Reeve AJ, Chapman V. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther 2008;10:R43.
63. Robinson I, Sargent B, Hatcher JP. Use of dynamic weight bearing as a novel end-point for the assessment of Freund's Complete Adjuvant induced hypersensitivity in mice. Neurosci Lett 2012;524:107-10.
64. Sagar DR, Staniaszek LE, Okine BN, Woodhams S, Norris LM, Pearson RG, Garle MJ, Alexander SPH, Bennett AJ, Barrett DA, Kendall DA, Scammell BE, Chapman V. Tonic modulation of spinal hyperexcitability by the endocannabinoid receptor system in a rat model of osteoarthritis pain. Arthritis Rheum 2010;62:3666-76.
65. Schuelert N, Johnson MP, Oskins JL, Jassal K, Chambers MG, McDougall JJ. Local application of the endocannabinoid hydrolysis inhibitor URB597 reduces nociception in spontaneous and chemically induced models of osteoarthritis. PAIN 2011;152:975-81.
66. Schuelert N, McDougall JJ. Cannabinoid-mediated antinociception is enhanced in rat osteoarthritic knees. Arthritis Rheum 2008;58:145-53.
67. Starowicz K, Cristino L, Di Marzo V. TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications. Curr Pharm Des 2008;14:42-54. Available at: http://www. ncbi.nlm.nih.gov/pubmed/18220817.
68. Starowicz K, Di Marzo V. Non-psychotropic analgesic drugs from the endocannabinoid system: "magic bullet" or "multiple-target" strategies? Eur J Pharmacol 2013;716:41-53.
69. Starowicz K, Makuch W, Korostynski M, Malek N, Slezak M, Zychowska M, Petrosino S, De Petrocellis L, Cristino L, Przewlocka B, Di Marzo V. Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism. PLoS One 2013;8:e60040.
70. Sumariwalla PF, Gallily R, Tchilibon S, Fride E, Mechoulam R, Feldmann M. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum 2004;50:985-98.
71. Tétreault P, DansereauM-A, Doré-Savard L, Beaudet N, Sarret P. Weight bearing evaluation in inflammatory, neuropathic and cancer chronic pain in freely moving rats. Physiol Behav 2011;104:495-502.
72. Tonge DP, Pearson MJ, Jones SW. The hallmarks of osteoarthritis and the potential to develop personalised disease-modifying pharmacological therapeutics. Osteoarthritis Cartilage 2014;22:609-21.
73. Tsujino H, Kondo E, Fukuoka T, Dai Y, Tokunaga A, Miki K, Yonenobu K, Ochi T, Noguchi K. Activating transcription factor 3 (ATF3) induction by axotomy in sensory and motoneurons: A novel neuronal marker of nerve injury. Mol Cell. Neurosci 2000;15:170-82.
74. Valdes AM, De Wilde G, Doherty SA, Lories RJ, Vaughn FL, Laslett LL, Maciewicz RA, Soni A, Hart DJ, Zhang W, Muir KR, Dennison EM, Wheeler M, Leaverton P, Cooper C, Spector TD, Cicuttini FM, Chapman V, Jones G, Arden NK, Doherty M. The Ile585Val TRPV1 variant is involved in risk of painful knee osteoarthritis. Ann Rheum Dis 2011;70:1556-61.
75. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. PAIN 1983;16:109-10. Available at: http://www. ncbi.nlm.nih.gov/pubmed/6877845.